A5039374832- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Cytomegalovirus and herpesvirus research
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Polyomavirus and related diseases
- Viral-associated cancers and disorders
- Childhood Cancer Survivors' Quality of Life
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- Renal Transplantation Outcomes and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Viral Infectious Diseases and Gene Expression in Insects
- Monoclonal and Polyclonal Antibodies Research
- Neutropenia and Cancer Infections
- RNA Interference and Gene Delivery
- Histone Deacetylase Inhibitors Research
City of Hope
2016-2025
City Of Hope National Medical Center
2016-2025
Beckman Research Institute
2015-2024
Duke Medical Center
2016-2024
University of North Carolina at Chapel Hill
2023
CTI BioPharma (United Kingdom)
2016-2023
Quest Diagnostics (United States)
2023
Emory University
2014-2023
Durham VA Medical Center
2023
American College of Rheumatology
2023
A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated interleukin-13 alpha 2 (IL13Rα2). Multiple infusions of CAR were administered over 220 days through two intracranial delivery routes - into resected tumor cavity followed by ventricular system. Intracranial IL13Rα2-targeted not associated any toxic effects grade 3 or higher. After T-cell treatment, regression all and spinal tumors was observed, along...
Abstract Purpose: A first-in-human pilot safety and feasibility trial evaluating chimeric antigen receptor (CAR)–engineered, autologous primary human CD8+ cytotoxic T lymphocytes (CTL) targeting IL13Rα2 for the treatment of recurrent glioblastoma (GBM). Experimental Design: Three patients with GBM were treated IL13(E13Y)-zetakine CTL IL13Rα2. Patients received up to 12 local infusions at a maximum dose 108 CAR-engineered cells via catheter/reservoir system. Results: We demonstrate...
Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions cyclophosphamide in patients scleroderma.
Immunotherapeutic ablation of lymphoma is a conceptually attractive treatment strategy that the subject intense translational research. Cytotoxic T lymphocytes (CTLs) are genetically modified to express CD19- or CD20-specific, single-chain antibody–derived chimeric antigen receptors (CARs) display HLA-independent antigen-specific recognition/killing targets. Here, we describe our initial experience in applying CAR-redirected autologous CTL adoptive therapy patients with recurrent lymphoma....
Abstract Chimeric antigen receptors (CAR) combine an antigen-binding domain with a CD3-ζ signaling motif to redirect T-cell specificity clinically important targets. First-generation CAR, such as the CD19-specific CAR (designated CD19R), may fail fully engage genetically modified T cells because activation is initiated by antigen-dependent through chimeric CD3-ζ, independent of costimulation accessory molecules. We show that enforced expression full-length costimulatory molecule CD28 in...
Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant human disorder of bone formation that causes developmental skeletal defects and extensive debilitating within soft connective tissues (heterotopic ossification) during childhood. All patients with classic clinical features FOP (great toe malformations progressive heterotopic have previously been found to carry the same heterozygous mutation (c.617G>A; p.R206H) in glycine serine residue (GS) activation domain activin A type...
Purpose Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by somatic mutations in the blood otherwise healthy adults. We hypothesized that patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at time ASCT would be associated with increased risk myelodysplastic syndrome and acute myeloid leukemia, collectively termed therapy-related neoplasm (TMN), other adverse outcomes. Methods performed whole-exome sequencing on...
AIDS patients who develop lymphoma are often treated with transplanted hematopoietic progenitor cells. As a first step in developing cell-based gene therapy treatment, four undergoing treatment these cells were also given gene-modified peripheral blood-derived (CD34(+)) expressing three RNA-based anti-HIV moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme). In vitro analysis of showed no differences their potential compared nontransduced estimates successful expression the...
Abstract The interleukin (IL) 13 receptor α2 (IL13Rα2) is a glioma-restricted cell-surface epitope not otherwise detected within the central nervous system. Here, we describe novel approach for targeting glioblastoma multiforme (GBM) with IL13Rα2-specific cytolytic T cells (CTLs) by their genetic modification to express membrane-tethered IL13 cytokine chimeric T-cell antigen receptor, or zetakine. Our prototype zetakine incorporates an E13Y mutein selective binding IL13Rα2. Human...